| 12.16 -0.01 (-0.08%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.68  |
1-year : | 15.83 |
| Resists | First : | 12.57 |
Second : | 13.56 |
| Pivot price | 12.33 |
|||
| Supports | First : | 10.97 |
Second : | 9.13 |
| MAs | MA(5) : | 12.1 |
MA(20) : | 12.31 |
| MA(100) : | 9.56 |
MA(250) : | 0 | |
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 41.1 |
D(3) : | 40.3 |
| RSI | RSI(14): 53.1 |
|||
| 52-week | High : | 21 | Low : | 5.9 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ARVN ] has closed above bottom band by 41.8%. Bollinger Bands are 15.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.2 - 12.27 | 12.27 - 12.32 |
| Low: | 11.77 - 11.87 | 11.87 - 11.94 |
| Close: | 12.03 - 12.18 | 12.18 - 12.28 |
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Thu, 18 Dec 2025
Possible Bearish Signals With Arvinas Insiders Disposing Stock - Sahm
Wed, 17 Dec 2025
Barclays Raises Price Target for Arvinas (ARVN) to $18 | ARVN St - GuruFocus
Mon, 15 Dec 2025
Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN - MarketBeat
Fri, 12 Dec 2025
Armistice Capital LLC Invests $4.12 Million in Arvinas, Inc. $ARVN - MarketBeat
Fri, 12 Dec 2025
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Sun, 30 Nov 2025
52,980 Shares in Arvinas, Inc. $ARVN Acquired by SG Americas Securities LLC - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 64 (M) |
| Shares Float | 56 (M) |
| Held by Insiders | 7.8 (%) |
| Held by Institutions | 96.4 (%) |
| Shares Short | 6,480 (K) |
| Shares Short P.Month | 7,760 (K) |
| EPS | -0.82 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.96 |
| Profit Margin | -18.8 % |
| Operating Margin | -105.1 % |
| Return on Assets (ttm) | -6.4 % |
| Return on Equity (ttm) | -10.2 % |
| Qtrly Rev. Growth | -59.1 % |
| Gross Profit (p.s.) | 4.86 |
| Sales Per Share | 4.86 |
| EBITDA (p.s.) | -1.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -328 (M) |
| Levered Free Cash Flow | -135 (M) |
| PE Ratio | -15.02 |
| PEG Ratio | 0 |
| Price to Book value | 1.52 |
| Price to Sales | 2.5 |
| Price to Cash Flow | -2.39 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|